Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1973 | 1 |
1977 | 1 |
1978 | 1 |
1980 | 1 |
1982 | 3 |
1983 | 1 |
1984 | 4 |
1985 | 5 |
1986 | 6 |
1987 | 8 |
1988 | 16 |
1989 | 4 |
1990 | 3 |
1991 | 1 |
1992 | 5 |
1993 | 5 |
1994 | 6 |
1995 | 5 |
1996 | 1 |
1997 | 1 |
1998 | 1 |
1999 | 8 |
2000 | 9 |
2001 | 10 |
2002 | 11 |
2003 | 17 |
2004 | 11 |
2005 | 16 |
2006 | 11 |
2007 | 23 |
2008 | 17 |
2009 | 16 |
2010 | 24 |
2011 | 13 |
2012 | 12 |
2013 | 27 |
2014 | 42 |
2015 | 49 |
2016 | 49 |
2017 | 66 |
2018 | 84 |
2019 | 89 |
2020 | 115 |
2021 | 122 |
2022 | 116 |
2023 | 116 |
2024 | 140 |
2025 | 61 |
Search Results
1,178 results
Results by year
RESULTS: After a year on ocrelizumab, 85 patients (73.9%) achieved NEDA-3. Thirty patients did not achieve NEDA: 20 (17.4%) because of INFL and 10 (8.7%) because of PIRA. ...After a year, NEDA-3 and INFL patients showed similar decreases in sNfL (p < 0.000
…PD patients treated with NEDA or NEDA+open LD had a lower risk of wearing-off implications than those treated with LD (all p < 0.05). ...CONCLUSION: NEDA therapy reduces motor symptoms and improves ADLs in early PD. The odds of developing motor complicatio
…